Brain trauma affects millions. Learn about traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) and how they impact civilians and Veterans.
Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.
Our approach is to build enabling platforms with strategic partners and to adopt a team science approach to fast-track solutions in years, not decades.
Magali Haas, MD, PhD CEO & President, Cohen Veterans Bioscience
Dr. Haas is founder of Cohen Veterans Bioscience (CVB), a global organization that leads pioneering efforts in PTSD and TBI research, including clinical trials, biotechnology, genetics, and biomarker discovery. She has more than 15 years of pharmaceutical leadership experience in neuroscience clinical development, translational medicine, and diagnostics, primarily at J&J. Dr. Haas has spearheaded the Brain Trauma Blueprint initiative to establish a national roadmap for PTSD & TBI precision therapeutics research.
Speakers:
Chantelle Ferland-Beckham, PhD Director of Policy & Advocacy, Cohen Veterans Bioscience
Atkinson, Arthur & Colburn, Wayne & Degruttola, Victor & Demets, David & Downing, Gregory & Hoth, Daniel & Oates, John & Peck, Carl & Schooley, Robert & Spilker, Bert & Woodcock, Janet & Zeger, Scott. (2001). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*. Clin Pharmacol Ther. 69. 89-95.
Post-traumatic stress disorder (PTSD) affects veterans, active military personnel, and civilians. While treatments exist, they are not effective for many people, and very little is known about genetic risk factors for PTSD. One of the key challenges in developing better treatments – and preventative measures – is that the underlying biological mechanisms are not thoroughly understood. It is now clear that PTSD is partly a genetic disorder, meaning that some people are more predisposed to develop PTSD than others. Hence, a better understanding of the genetic risk factors of PTSD will help to develop new diagnostic tests and treatments for PTSD and inform strategies for preventing PTSD following exposure to trauma.
Modern genetic studies offer unique opportunities for discoveries that will fuel future treatment and prevention efforts. This talk will cover major findings from the last 25 years of PTSD genetics. Groundbreaking discoveries in recent years have identified specific genetic risk factors for PTSD. Such discoveries include those by the Psychiatric Genomics Consortium (PGC)-PTSD Working Group, which has conducted a powerful genome-wide association study (GWAS) of PTSD. This talk will describe how massive sample sizes (of hundreds of thousands of participants) were used to make these discoveries, what they mean for research and for individuals with PTSD, and what is possible in the near future.
Webinar Agenda:
– What is Genetics?
– Accelerating Discovery of Genetic Markers
– PTSD Genetics: Heritability, and Why Genetics is Useful!
– Major Findings in PTSD Genetics
– PGC-PTSD: Landmark Study & Future Efforts
– Group Question & Answer
Webinar originally hosted November 18, 2021.
Magali Haas, MD, PhD CEO & President, Cohen Veterans Bioscience
Dr. Haas is founder of Cohen Veterans Bioscience (CVB), a global organization that leads pioneering efforts in PTSD and TBI research, including clinical trials, biotechnology, genetics, and biomarker discovery. She has more than 15 years of pharmaceutical leadership experience in neuroscience clinical development, translational medicine, and diagnostics, primarily at J&J. Dr. Haas has spearheaded the Brain Trauma Blueprint initiative to establish a national roadmap for PTSD & TBI precision therapeutics research.
Jamshid Ghajar, MD, PhD, FACS President Emeritus, Brain Trauma Foundation
Dr. Ghajar is a board-certified neurosurgeon. In 2014, he joined the neurosurgery faculty at Stanford, where he is a clinical professor of neurosurgery and the Moghadam Family Director of the Stanford Brain Performance Center, Stanford University School of Medicine. He founded the Brain Trauma Foundation to develop and implement best practice guidelines for TBI, with the goal of improving patients’ lives.
Speakers:
Jennifer A. Sumner, PhD Assistant Professor, Department of Psychology, UCLA
Andreas Jeromin, PhD Chief Scientific Officer, Cohen Veterans Bioscience
Manage Cookie Consent
We use cookies to optimize our website.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
